{"id":"apixaban-single-dose","safety":{"commonSideEffects":[{"rate":"null","effect":"Bleeding"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Syncope"}]},"_chembl":{"chemblId":"CHEMBL231779","moleculeType":"Small molecule","molecularWeight":"459.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Apixaban selectively inhibits Factor Xa, a serine protease critical in both the intrinsic and extrinsic coagulation pathways. By blocking Factor Xa activity, it prevents the generation of thrombin and subsequent fibrin clot formation, thereby reducing thrombotic events. This direct mechanism allows for predictable pharmacokinetics and oral bioavailability without requiring monitoring.","oneSentence":"Apixaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:20.749Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Deep vein thrombosis and pulmonary embolism treatment and prevention"},{"name":"Acute coronary syndrome (in combination with antiplatelet therapy)"}]},"trialDetails":[{"nctId":"NCT04006093","phase":"PHASE1","title":"Apixaban in Subjects With Peritoneal Dialysis","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2019-12-08","conditions":"Chronic Renal Insufficiency, Peritoneal Dialysis","enrollment":24},{"nctId":"NCT04874428","phase":"PHASE1","title":"Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-05-19","conditions":"Liver Cirrhosis","enrollment":24},{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT07404345","phase":"PHASE4","title":"Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD)","status":"NOT_YET_RECRUITING","sponsor":"Hospital Civil de Guadalajara","startDate":"2026-03-01","conditions":"Hemodialysis Access Failure, Kidney Disease, End-Stage, Hemodialysis Catheter","enrollment":54},{"nctId":"NCT03968393","phase":"PHASE4","title":"Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2019-06-14","conditions":"Stroke, Atrial Fibrillation","enrollment":2270},{"nctId":"NCT06043297","phase":"PHASE1","title":"Bioequivalence Study of Two Products of Apixaban 5mg Tablets in Healthy, Adult, Human Subjects","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2023-02-23","conditions":"Antithrombic Drug","enrollment":30},{"nctId":"NCT06581965","phase":"PHASE4","title":"inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2024-11-11","conditions":"Venous Thromboembolism, Venous Thromboses, Pulmonary Embolism","enrollment":10078},{"nctId":"NCT05618808","phase":"PHASE2","title":"A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-05-24","conditions":"Venous Thromboembolism","enrollment":373},{"nctId":"NCT05735639","phase":"PHASE4","title":"THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2024-01-22","conditions":"Venous Thromboembolism, Varicose Veins","enrollment":6660},{"nctId":"NCT06689436","phase":"PHASE2","title":"Pivotal BE Study of TAH3311 ODF vs ELIQUIS® Tablet Under Fasted Condition in Healthy Volunteers","status":"COMPLETED","sponsor":"TAHO Pharmaceuticals Ltd.","startDate":"2024-11-16","conditions":"Random Allocation, Intermittent Fasting, Enteral Feeding","enrollment":60},{"nctId":"NCT04437654","phase":"PHASE4","title":"The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2020-07-28","conditions":"Atrial Fibrillation Patients With Intermediate Stroke Risk","enrollment":1800},{"nctId":"NCT03062319","phase":"PHASE4","title":"Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis","status":"TERMINATED","sponsor":"National Hospital Organization Osaka National Hospital","startDate":"2017-04-06","conditions":"Ischemic Stroke, Atrial Fibrillation, Atherothrombosis","enrollment":321},{"nctId":"NCT06372483","phase":"PHASE1","title":"Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant","status":"ACTIVE_NOT_RECRUITING","sponsor":"VarmX B.V.","startDate":"2024-02-21","conditions":"Coagulation Disorder","enrollment":40},{"nctId":"NCT02735902","phase":"PHASE4","title":"Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2017-06-01","conditions":"Transcatheter Aortic Valve Replacement","enrollment":170},{"nctId":"NCT06388239","phase":"PHASE1","title":"Bioequivalence Study of Apixaban 5 mg Film-coated Tablets in Healthy Thai Volunteers","status":"NOT_YET_RECRUITING","sponsor":"International Bio service","startDate":"2024-08-26","conditions":"Healthy Volunteer","enrollment":28},{"nctId":"NCT06168370","phase":"NA","title":"Personalized, CT-guided Antithrombotic Therapy Versus Lifelong Single Antiplatelet Therapy to Reduce Thromboembolic and Bleeding Events in Non-atrial Fibrillation Patients After Transcatheter Aortic Valve Implantation","status":"RECRUITING","sponsor":"St. Antonius Hospital","startDate":"2023-12-01","conditions":"Severe Aortic Valve Stenosis","enrollment":2500},{"nctId":"NCT04344717","phase":"PHASE4","title":"Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-12-20","conditions":"Short Bowel Syndrome, Anticoagulation","enrollment":84},{"nctId":"NCT03864406","phase":"PHASE1","title":"Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2019-06-04","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT05995119","phase":"EARLY_PHASE1","title":"Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers","status":"COMPLETED","sponsor":"TAHO Pharmaceuticals Ltd.","startDate":"2022-12-05","conditions":"Healthy Volunteers, Fasting, Fed","enrollment":12},{"nctId":"NCT01758432","phase":"PHASE2","title":"Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2012-12","conditions":"Healthy Volunteers","enrollment":54},{"nctId":"NCT05973188","phase":"PHASE4","title":"Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial","status":"UNKNOWN","sponsor":"Peshawar Institute of Cardiology","startDate":"2023-05-01","conditions":"Left Ventricular Thrombus","enrollment":141},{"nctId":"NCT05152420","phase":"PHASE1","title":"Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects","status":"COMPLETED","sponsor":"VarmX B.V.","startDate":"2021-10-29","conditions":"Coagulation Disorder","enrollment":105},{"nctId":"NCT05841446","phase":"PHASE1","title":"Bioequivalence Study of Apixaban Tablets in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2021-03-02","conditions":"Healthy","enrollment":54},{"nctId":"NCT04432220","phase":"PHASE4","title":"AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2020-07-28","conditions":"Atrial Fibrillation Patients With Moderate or High Stroke Risk Who Had Undergone Catheter Ablation of Atrial Fibrillation","enrollment":840},{"nctId":"NCT04895553","phase":"","title":"Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-08-01","conditions":"Glioma, Malignant","enrollment":60},{"nctId":"NCT05491460","phase":"PHASE1","title":"Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects","status":"UNKNOWN","sponsor":"Doasense GmbH","startDate":"2022-07-01","conditions":"Anticoagulant Therapy","enrollment":24},{"nctId":"NCT02369653","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-10-22","conditions":"Lymphoma, Acute Lymphoblastic Leukemia","enrollment":512},{"nctId":"NCT04191928","phase":"PHASE1","title":"Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2020-03-03","conditions":"Pancreas Cancer, DVT, Pulmonary Embolism","enrollment":4},{"nctId":"NCT04023760","phase":"PHASE4","title":"Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2019-06-26","conditions":"Pharmacokinetics, Kidney Transplant, Lung Transplant","enrollment":14},{"nctId":"NCT01707394","phase":"PHASE1","title":"Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-01-10","conditions":"Thromboembolism","enrollment":49},{"nctId":"NCT04788355","phase":"PHASE3","title":"Prevention of Complications (SARS-CoV-2): Clinical Study","status":"COMPLETED","sponsor":"Universidade do Vale do Sapucai","startDate":"2020-07-01","conditions":"Complication","enrollment":176},{"nctId":"NCT04412291","phase":"PHASE2","title":"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2020-06-11","conditions":"Covid-19","enrollment":120},{"nctId":"NCT03398434","phase":"PHASE2","title":"Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-16","conditions":"Atrial Fibrillation","enrollment":""},{"nctId":"NCT03276143","phase":"PHASE2","title":"FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-09-21","conditions":"Knee Arthroplasty, Total","enrollment":813},{"nctId":"NCT03509883","phase":"PHASE1","title":"Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-04-26","conditions":"Healthy Volunteers","enrollment":94},{"nctId":"NCT03251482","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-13","conditions":"VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery","enrollment":308},{"nctId":"NCT02599532","phase":"PHASE1","title":"Pharmacokinetics of Apixaban in Nephrotic Syndrome","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2017-04-30","conditions":"Nephrotic Syndrome, Proteinuria","enrollment":21},{"nctId":"NCT01962545","phase":"PHASE4","title":"Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study","status":"COMPLETED","sponsor":"Satoshi Shizuta","startDate":"2013-11-05","conditions":"Atrial Fibrillation, Coronary Artery Disease","enrollment":690},{"nctId":"NCT03083782","phase":"PHASE1","title":"Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2017-04-18","conditions":"Venous Thromboembolism, Pharmacokinetics, Healthy","enrollment":12},{"nctId":"NCT02912234","phase":"PHASE1","title":"Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-09","conditions":"Venous Thromboembolism","enrollment":20},{"nctId":"NCT01340586","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-06","conditions":"End Stage Renal Disease","enrollment":18},{"nctId":"NCT02034565","phase":"PHASE1","title":"Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-02","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT02034578","phase":"PHASE1","title":"Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-07","conditions":"Healthy Volunteers","enrollment":75},{"nctId":"NCT02034591","phase":"PHASE1","title":"Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-10","conditions":"Healthy Subjects","enrollment":37},{"nctId":"NCT02101112","phase":"PHASE1","title":"Bioavailability of Apixaban Crushed Tablet","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-03","conditions":"Thrombosis","enrollment":69},{"nctId":"NCT02074358","phase":"PHASE1","title":"A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02","conditions":"Anticoagulation","enrollment":43},{"nctId":"NCT01437839","phase":"PHASE1","title":"Food Effect Study For Apixaban Commercial Image Tablets","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09","conditions":"Healthy","enrollment":22},{"nctId":"NCT00914641","phase":"PHASE1","title":"Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06","conditions":"Thrombosis","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eliquis single dose"],"phase":"marketed","status":"active","brandName":"Apixaban single dose","genericName":"Apixaban single dose","companyName":"Universitaire Ziekenhuizen KU Leuven","companyId":"universitaire-ziekenhuizen-ku-leuven","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Apixaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis and pulmonary embolism treatment and prevention, Acute coronary syndrome (in combination with antiplatelet therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}